News | March 20, 2026
Clariant boosts US pharmaceutical production with Clear Lake expansion
The Clear Lake facility marks Clariant’s first U.S. site dedicated to PEG excipient production
The Clear Lake facility marks Clariant’s first U.S. site dedicated to PEG excipient production
The drug also showed a manageable safety profile, with just 6.4% of patients stopping treatment due to side effects. No new safety concerns emerged
The facility supports drug discovery, biomolecular research, and the development of next-generation diagnostics
The facility features 2,176 high-performance GPUs across the US and Europe
At the center of the collapse is opposition from the Federal Trade Commission
The initial consideration for the transaction is US$ 12 million
ILUMYA has already earned FDA approvals for scalp and nail plaque psoriasis in April 2024 and December 2025
The approval of Cosentyx represents an important advancement for younger HS patients who have had limited treatment options
The partnership will focus on advancing fault-tolerant quantum algorithms and developing clinically relevant quantum applications
The deal also includes upfront licensing fees and milestone-based payments from Lupin to Zydus
Subscribe To Our Newsletter & Stay Updated
